Company intelligence / Profile preview
Lumosa Therapeutics
Taipei, Taipei City, Taiwanlumosa.com.tw ↗
- Ownership
- Public · 6535
- Employees
- ~43
- Development stage
- Phase 3
01
Overview
Lumosa Therapeutics has one marketed product for postoperative pain relief, Naldebain® (LT1001). Its lead pipeline asset LT3001 for acute ischemic stroke is in Phase II clinical trials. LT5001 for uremic pruritus has completed Phase I. Additional assets are in pre-clinical development targeting neurological disorders and oncology. The company’s focus remains on diseases with urgent unmet medical needs in neurology and oncology
- Therapeutic areas
- OncologyCardiovascularNeurologyNephrology
- Modalities
- Small molecules (based on pipeline and product descriptions)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
No specific major pharma partnerships listed; Center Laboratories, Inc. holds a significant equity stake (~34%). Other investors include Yulon Motor Company Ltd., Sun Ten Pharmaceutical Co. Ltd., Farglory Life Insurance Co., Yuanta Venture Capital Co.
Beyond the preview
Go deeper on Lumosa Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lumosa Therapeutics.